INTS
Intensity Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
None
5 analysts
$4.15
+$0.05 (+1.22%)
Target:
$24.80
(497.6%)
Sign in to add INTS to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $11.22M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.54 |
| EPS (TTM) | $-4.01 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -207.37% |
| Debt/Equity | 1.02 |
| Recommendation | None |
| Analyst Target | $24.80 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 65.9 |
| Beta | 3.06 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $43.50 |
| 52-Week Low | $3.51 |
| 50-Day Avg | $4.50 |
| 200-Day Avg | $7.58 |
| Avg Volume | 38.9K |
| Volume | 59.6K |
Performance Analysis
BULLISHINTS shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($3.51), which could present a value opportunity.
+
RSI at 65.9 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 5 analysts.
+
Average analyst target of $24.80 implies 497.6% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report